This excerpt taken from the INCY 8-K filed Nov 2, 2006.
We have completed the single- and multiple-dose-escalation Phase I trials in healthy volunteers for our lead oral CCR5 antagonist, INCB9471, and initiated a 14-day Phase IIa trial evaluating INCB9471 as monotherapy in treatment-naïve HIV-infected patients and treatment-experienced HIV-infected patients not currently on HIV therapy. Top-line safety and efficacy results from this trial are expected early in 2007.
In parallel with the development of INCB9471, we plan to file an IND for a second CCR5 compound, INCB15050, and begin Phase I testing in healthy volunteers by year-end.
This excerpt taken from the INCY 8-K filed Jul 27, 2006.